サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1739215

ポリオ・ワクチンの世界市場

Polio Vaccines

出版日
ページ情報
英文 277 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
ポリオ・ワクチンの世界市場
出版日: 2025年05月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 277 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ポリオ・ワクチンの世界市場は2030年までに9億7,920万米ドルに達する見込み

2024年に8億900万米ドルと推定されるポリオ・ワクチンの世界市場は、分析期間2024-2030年にCAGR 3.2%で成長し、2030年には9億7,920万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである不活化ポリオワクチンは、CAGR 2.6%を記録し、分析期間終了時には6億2,400万米ドルに達すると予測されます。経口ポリオワクチン分野の成長率は、分析期間中CAGR 4.5%と推定されます。

米国市場は2億2,040万米ドルと推定、中国はCAGR 5.9％で成長予測

米国のポリオ・ワクチン市場は、2024年に2億2,040万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億9,210万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3％と2.5％と予測されています。欧州では、ドイツがCAGR 1.8%で成長すると予測されています。

世界のポリオ・ワクチン市場- 主要動向と促進要因のまとめ

ポリオ・ワクチンはほぼ撲滅されたにもかかわらず、なぜ世界の公衆衛生の要であり続けるのか？

ポリオ・ワクチンは、ポリオウイルスによって引き起こされる、致命的な感染症であるポリオ性骨髄炎の撲滅を目指す、これまでに行われた中で最も野心的な世界的公衆衛生キャンペーンの基盤となってきました。大きな進展があったとはいえ、野生ポリオウイルスが蔓延している国はわずかであり、ワクチン接種を継続することは、再流行の危険性、ワクチン由来のポリオウイルス株、世界の移動性などの理由から、依然として重要です。経口ポリオワクチン（OPV）と不活化ポリオワクチン（IPV）という2種類の主要なワクチンは、感染リスク、ヘルスケア・インフラ、規制の枠組みによって地域が異なるもの、依然として予防接種戦略の中心となっています。

OPV、特に二価ワクチン（bOPV）と新型経口ポリオワクチン2型（nOPV2）は、投与が容易であり、腸管免疫とウイルス排出によって地域住民を予防することができるため、集団予防接種キャンペーンで広く使用されています。一方、IPVは安全性が高く、ワクチン由来株のリスクがないため、高所得国や定期予防接種のスケジュールで好まれています。世界保健社会がポリオ終息戦略へと移行する中、免疫を確保し、流行を予防し、長期的な根絶を達成するために、IPVとnOPV2の同時接種が優先されています。

技術の進歩や戦略的製剤によって、ワクチンの有効性と安全性はどのように向上しているのでしょうか？

ワクチンの研究開発は、免疫原性が改善され、ワクチン由来ポリオウイルス（cVDPV）が循環するリスクがより低い、より安全で安定したワクチンの開発を目指して進化してきました。遺伝的に安定した減弱プロファイルを持つnOPV2の導入は、以前のOPV製剤に関連して発生した2型ポリオウイルスの課題に対処する画期的なものです。このワクチンは、WHOの緊急使用リストに掲載され、神経ウイルス性復帰株の出現を抑えるという有望な初期結果を示しています。

コールドチェーン・ロジスティクス、凍結乾燥、プレフィルド注射剤形式の進歩により、特に遠隔地や紛争の影響を受けている地域では、ポリオ・ワクチンの使用範囲と保存期間がさらに拡大しています。IPVとジフテリア、百日咳、破傷風を組み合わせた混合ワクチン（DPT-IPV）は、その効率性と接種範囲の広さから、定期予防接種プログラムで普及しつつあります。また、予防接種キャンペーンにおけるデジタル予防接種登録、バーコード付きバイアル、地理空間マッピングの活用により、トレーサビリティ、モニタリング、データ主導の展開が改善され、予防接種の有効性とアカウンタビリティが向上しています。

ポリオ・ワクチンの配布と普及を推進する世界のアライアンスと地域プログラムとは？

WHO、ユニセフ、米国CDC、国際ロータリー、ビル・アンド・メリンダ・ゲイツ財団が主導する世界ポリオ撲滅推進計画（GPEI）は、30年以上にわたり、ワクチン資金調達、調整、現地展開の主要な原動力となってきました。全国予防接種日（NID）、戸別訪問キャンペーン、発生時対応予防接種活動（ORI）はいずれも、世界のポリオ・ワクチン接種率を高める上で極めて重要な役割を果たしてきました。保健インフラが脆弱な国や紛争地域は依然として優先地域であり、的を絞ったキャンペーンや国境を越えた連携が必要です。

南アジアとサハラ以南のアフリカは、歴史的にワクチン接種の中心地でしたが、現在ではほとんどの地域で3価OPV（tOPV）からbOPVとIPVに移行しています。アフガニスタンとパキスタンは依然として野生ポリオウイルスの最後の砦であり、継続的なサーベイランスと高頻度の予防接種が必要となっています。北米や欧州などの先進地域では、IPVが国の予防接種スケジュールにおける標準となっており、現在では、予防態勢の強化と集団免疫の維持に重点が移りつつあります。世界の根絶が近づくにつれ、地域的なサーベイランスと持続的なワクチン摂取が、再流行を防ぐために不可欠となります。

ポリオ・ワクチン市場における長期的な戦略集中とイノベーションの原動力は？

ポリオ・ワクチン市場の成長の原動力は、現在進行中の世界の撲滅活動、cVDPVアウトブレイクの発生、そして国際的な健康安全保障の義務化です。撲滅活動によって定期接種ポリオワクチンの市場規模は最終的に縮小する可能性がありますが、緊急対応、移行計画、備蓄の必要性から、短期・中期的な需要は引き続き高いと予想されます。各国政府とNGOは、ポリオの不可逆的な撲滅を確実にするため、高い接種率を維持し、ワクチンの備蓄に尽力しています。

メーカー各社は戦略的に、生物学的安全性を高め、製造コストを削減するため、ベロ細胞やセービン株のプラットフォームを用いた次世代IPV製造に投資しています。特にインド、インドネシア、アフリカの一部では、技術移転と現地生産への取り組みが地域のサプライチェーン回復力を高めています。官民パートナーシップ、ユニセフとGaviによる共同調達、ワクチンの包装と配送における継続的な技術革新は、世界の予防接種インフラを強化しています。ポリオの終息が近づくにつれ、ワクチン市場は数量ベースの供給から、完全かつ持続的な撲滅を目指す戦略的備蓄主導型の精密展開モデルへと軸足を移していくと思われます。

セグメント

タイプ別（不活化ポリオワクチン,経口ポリオワクチン）;エンドユーザー別（病院・診療所エンドユーザー,公共サービスエンドユーザー,その他エンドユーザー）

調査対象企業の例（注目の43社）

  • Adithya Vaccine Pharma
  • Astellas Pharma Inc.
  • Beijing Tiantan Biological Products Corp
  • Bharat Biotech International Ltd.
  • Bharat Immunologicals and Biologicals Corporation Limited（BIBCOL）
  • Bio Farma
  • Bio-Med Healthcare Products Pvt. Ltd.
  • Biomed-Lublin
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline（GSK）
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP34223

Global Polio Vaccines Market to Reach US$979.2 Million by 2030

The global market for Polio Vaccines estimated at US$809.0 Million in the year 2024, is expected to reach US$979.2 Million by 2030, growing at a CAGR of 3.2% over the analysis period 2024-2030. Inactivated Polio Vaccine, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$624.0 Million by the end of the analysis period. Growth in the Oral Polio Vaccine segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$220.4 Million While China is Forecast to Grow at 5.9% CAGR

The Polio Vaccines market in the U.S. is estimated at US$220.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$192.1 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Polio Vaccines Market - Key Trends & Drivers Summarized

Why Do Polio Vaccines Remain a Cornerstone of Global Public Health Despite Near-Eradication?

Polio vaccines have been the foundation of one of the most ambitious global public health campaigns ever undertaken-aiming to eliminate poliomyelitis, a crippling and potentially fatal infectious disease caused by the poliovirus. Despite significant progress, with wild poliovirus now endemic in only a few countries, continued vaccination remains critical due to risks of re-emergence, vaccine-derived poliovirus strains, and global mobility. Two primary vaccine types-oral polio vaccine (OPV) and inactivated polio vaccine (IPV)-remain central to immunization strategies in different regions depending on transmission risk, healthcare infrastructure, and regulatory frameworks.

OPV, particularly the bivalent (bOPV) and novel oral polio vaccine type 2 (nOPV2), is widely used in mass immunization campaigns due to its ease of administration and ability to confer community protection through gut immunity and viral shedding. IPV, on the other hand, is preferred in high-income countries and in routine immunization schedules for its safety profile and lack of risk for vaccine-derived strains. As the global health community transitions to a polio endgame strategy, the co-administration of IPV and nOPV2 is being prioritized to ensure immunity, prevent outbreaks, and achieve long-term eradication.

How Are Technological Advancements and Strategic Formulations Enhancing Vaccine Efficacy and Safety?

Vaccine R&D has evolved to develop safer and more stable polio vaccines with improved immunogenicity and a lower risk of circulating vaccine-derived poliovirus (cVDPV). The introduction of nOPV2, engineered with genetically stabilized attenuation profiles, represents a breakthrough in addressing the challenges posed by type 2 poliovirus outbreaks linked to earlier OPV formulations. This vaccine is being deployed under WHO’s Emergency Use Listing and has shown promising early field results in limiting the emergence of neurovirulent revertants.

Advances in cold chain logistics, freeze-drying, and prefilled injectable formats have further expanded the reach and shelf life of polio vaccines, particularly in remote or conflict-affected regions. Combination vaccines incorporating IPV with diphtheria, pertussis, and tetanus (DPT-IPV) are gaining traction in routine immunization programs for their efficiency and broader coverage. The use of digital immunization registries, barcoded vials, and geospatial mapping in immunization campaigns is also improving traceability, monitoring, and data-driven deployment, thereby enhancing vaccination efficacy and accountability.

Which Global Alliances and Regional Programs Are Driving Polio Vaccine Distribution and Coverage?

The Global Polio Eradication Initiative (GPEI)-led by WHO, UNICEF, the U.S. CDC, Rotary International, and the Bill & Melinda Gates Foundation-has been the primary driver of vaccine funding, coordination, and field deployment for over three decades. National immunization days (NIDs), door-to-door campaigns, and outbreak response immunization efforts (ORIs) have all played pivotal roles in raising global polio vaccine coverage. Countries with weak health infrastructure or conflict zones remain priority areas, requiring targeted campaigns and cross-border coordination.

South Asia and sub-Saharan Africa have historically been focal points for vaccine delivery, although most regions have now transitioned from trivalent OPV (tOPV) to bOPV and IPV. Afghanistan and Pakistan remain the last strongholds of wild poliovirus, necessitating ongoing surveillance and high-frequency immunization drives. In developed regions such as North America and Europe, IPV is standard in national immunization schedules, with focus now shifting to bolstering preparedness and maintaining herd immunity. As global eradication inches closer, regional surveillance and sustained vaccine uptake will be essential to prevent resurgence.

What Is Driving Long-Term Strategic Focus and Innovation in the Polio Vaccines Market?

The growth in the polio vaccines market is driven by ongoing global eradication efforts, emergence of cVDPV outbreaks, and international health security mandates. While eradication may ultimately reduce the size of the routine polio vaccine market, short- to medium-term demand is expected to remain high due to emergency responses, transition plans, and stockpile requirements. Governments and NGOs are committed to maintaining high coverage and vaccine stockpiles to ensure polio’s irreversible elimination.

Strategically, manufacturers are investing in next-generation IPV production using Vero cell and Sabin strain platforms to increase biosafety and reduce production costs. Technology transfers and local manufacturing initiatives-especially in India, Indonesia, and parts of Africa-are enhancing regional supply chain resilience. Public-private partnerships, pooled procurement by UNICEF and Gavi, and continued innovation in vaccine packaging and delivery are reinforcing the global vaccination infrastructure. As the polio endgame approaches, the vaccine market will pivot from volume-based supply to a strategic reserve-driven, precision-deployment model aimed at complete and sustained eradication.

SCOPE OF STUDY:

The report analyzes the Polio Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Inactivated Polio Vaccine, Oral Polio Vaccine); End-Use (Hospitals & Clinics End-Use, Public Services End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Adithya Vaccine Pharma
  • Astellas Pharma Inc.
  • Beijing Tiantan Biological Products Corp
  • Bharat Biotech International Ltd.
  • Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL)
  • Bio Farma
  • Bio-Med Healthcare Products Pvt. Ltd.
  • Biomed-Lublin
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline (GSK)
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Polio Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Conducive Government Policies and Polio Eradication Activities Drive Vaccine Demand
    • Technological Innovations Enhance Vaccine Development and Distribution Efficiency
    • Increase in Infant Population and Immunization Programs Supports Market Growth
    • Global Health Initiatives and Partnerships Strengthen Vaccination Campaigns
    • Emergence of Combination Vaccines Simplifies Immunization Schedules
    • Advancements in Cold Chain Logistics Improve Vaccine Storage and Transportation
    • Expansion of Routine Immunization Programs in Developing Countries Boosts Coverage
    • Regulatory Approvals and WHO Prequalification Facilitate Market Entry of New Vaccines
    • Investment in Research and Development Accelerates Introduction of Novel Formulations
    • Public Awareness Campaigns and Education Initiatives Increase Vaccine Acceptance
    • Integration of Digital Health Records Enhances Tracking and Monitoring of Immunization
    • Challenges in Vaccine Hesitancy and Misinformation Necessitate Targeted Communication Strategies
    • Development of Oral Polio Vaccines (OPV) and Inactivated Polio Vaccines (IPV) Offers Diverse Options
    • Strategic Collaborations Between Governments and Pharmaceutical Companies Strengthen Supply Chains
    • Focus on Cost-Effective Manufacturing Processes Improves Affordability and Accessibility
    • Implementation of Surveillance Systems Aids in Early Detection and Response to Outbreaks
    • Expansion into Emerging Markets Presents Opportunities for Market Penetration
    • Continuous Monitoring and Evaluation of Vaccine Efficacy Ensures Public Health Safety
    • Adoption of Innovative Delivery Methods Enhances Immunization Coverage
    • Ongoing Efforts Toward Global Polio Eradication Sustain Long-Term Market Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Polio Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Polio Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Polio Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Polio Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Inactivated Polio Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Inactivated Polio Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Inactivated Polio Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Oral Polio Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Oral Polio Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Oral Polio Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Public Services End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Public Services End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Public Services End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Polio Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Polio Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Polio Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Polio Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Polio Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Polio Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Polio Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Polio Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Polio Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Polio Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Polio Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Polio Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Polio Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Polio Vaccines by Type - Inactivated Polio Vaccine and Oral Polio Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Polio Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Polio Vaccine and Oral Polio Vaccine for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Polio Vaccines by End-Use - Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Polio Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Public Services End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION